PMC:7029759 / 14371-15165 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"322","span":{"begin":32,"end":40},"obj":"Species"},{"id":"323","span":{"begin":126,"end":135},"obj":"Species"},{"id":"324","span":{"begin":229,"end":237},"obj":"Species"},{"id":"325","span":{"begin":407,"end":415},"obj":"Species"},{"id":"326","span":{"begin":477,"end":484},"obj":"Species"},{"id":"327","span":{"begin":659,"end":666},"obj":"Species"},{"id":"328","span":{"begin":699,"end":706},"obj":"Species"},{"id":"329","span":{"begin":54,"end":63},"obj":"Disease"}],"attributes":[{"id":"A322","pred":"tao:has_database_id","subj":"322","obj":"Tax:9606"},{"id":"A323","pred":"tao:has_database_id","subj":"323","obj":"Tax:2697049"},{"id":"A324","pred":"tao:has_database_id","subj":"324","obj":"Tax:9606"},{"id":"A325","pred":"tao:has_database_id","subj":"325","obj":"Tax:9606"},{"id":"A326","pred":"tao:has_database_id","subj":"326","obj":"Tax:9606"},{"id":"A327","pred":"tao:has_database_id","subj":"327","obj":"Tax:9606"},{"id":"A328","pred":"tao:has_database_id","subj":"328","obj":"Tax:9606"},{"id":"A329","pred":"tao:has_database_id","subj":"329","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As the outbreak continues, more patients who survived infection will become available to serve as donors to make antisera for 2019-nCoV, and a sizeable stock of antisera could be developed to serve as a treatment for the sickest patients. Unfortunately, the exponential growth of the outbreak would work against this strategy, since the growing number of cases would likely outstrip the ability of previous patients to provide donor plasma as treatment. Moreover, convalescent patient sera would have significant variability in the potency of antiviral effect, making it less ideal 37. While transfusion medicine services should certainly pursue convalescent patient sera as an option right now for patient treatment, it is ultimately limited in its effective scope of controlling the outbreak."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T225","span":{"begin":113,"end":121},"obj":"UBERON:0001977"},{"id":"T224","span":{"begin":126,"end":135},"obj":"SP_7"},{"id":"T223","span":{"begin":161,"end":169},"obj":"UBERON:0001977"},{"id":"T222","span":{"begin":433,"end":439},"obj":"UBERON:0001969"},{"id":"T221","span":{"begin":485,"end":489},"obj":"UBERON:0001977"},{"id":"T220","span":{"begin":667,"end":671},"obj":"UBERON:0001977"},{"id":"T219","span":{"begin":769,"end":780},"obj":"GO:0065007"}],"text":"As the outbreak continues, more patients who survived infection will become available to serve as donors to make antisera for 2019-nCoV, and a sizeable stock of antisera could be developed to serve as a treatment for the sickest patients. Unfortunately, the exponential growth of the outbreak would work against this strategy, since the growing number of cases would likely outstrip the ability of previous patients to provide donor plasma as treatment. Moreover, convalescent patient sera would have significant variability in the potency of antiviral effect, making it less ideal 37. While transfusion medicine services should certainly pursue convalescent patient sera as an option right now for patient treatment, it is ultimately limited in its effective scope of controlling the outbreak."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T70","span":{"begin":433,"end":439},"obj":"Body_part"}],"attributes":[{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"As the outbreak continues, more patients who survived infection will become available to serve as donors to make antisera for 2019-nCoV, and a sizeable stock of antisera could be developed to serve as a treatment for the sickest patients. Unfortunately, the exponential growth of the outbreak would work against this strategy, since the growing number of cases would likely outstrip the ability of previous patients to provide donor plasma as treatment. Moreover, convalescent patient sera would have significant variability in the potency of antiviral effect, making it less ideal 37. While transfusion medicine services should certainly pursue convalescent patient sera as an option right now for patient treatment, it is ultimately limited in its effective scope of controlling the outbreak."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T41","span":{"begin":54,"end":63},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"As the outbreak continues, more patients who survived infection will become available to serve as donors to make antisera for 2019-nCoV, and a sizeable stock of antisera could be developed to serve as a treatment for the sickest patients. Unfortunately, the exponential growth of the outbreak would work against this strategy, since the growing number of cases would likely outstrip the ability of previous patients to provide donor plasma as treatment. Moreover, convalescent patient sera would have significant variability in the potency of antiviral effect, making it less ideal 37. While transfusion medicine services should certainly pursue convalescent patient sera as an option right now for patient treatment, it is ultimately limited in its effective scope of controlling the outbreak."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T122","span":{"begin":141,"end":142},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T123","span":{"begin":201,"end":202},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T124","span":{"begin":433,"end":439},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"As the outbreak continues, more patients who survived infection will become available to serve as donors to make antisera for 2019-nCoV, and a sizeable stock of antisera could be developed to serve as a treatment for the sickest patients. Unfortunately, the exponential growth of the outbreak would work against this strategy, since the growing number of cases would likely outstrip the ability of previous patients to provide donor plasma as treatment. Moreover, convalescent patient sera would have significant variability in the potency of antiviral effect, making it less ideal 37. While transfusion medicine services should certainly pursue convalescent patient sera as an option right now for patient treatment, it is ultimately limited in its effective scope of controlling the outbreak."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T54","span":{"begin":427,"end":432},"obj":"Chemical"},{"id":"T55","span":{"begin":543,"end":552},"obj":"Chemical"},{"id":"T56","span":{"begin":604,"end":612},"obj":"Chemical"}],"attributes":[{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_17891"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"As the outbreak continues, more patients who survived infection will become available to serve as donors to make antisera for 2019-nCoV, and a sizeable stock of antisera could be developed to serve as a treatment for the sickest patients. Unfortunately, the exponential growth of the outbreak would work against this strategy, since the growing number of cases would likely outstrip the ability of previous patients to provide donor plasma as treatment. Moreover, convalescent patient sera would have significant variability in the potency of antiviral effect, making it less ideal 37. While transfusion medicine services should certainly pursue convalescent patient sera as an option right now for patient treatment, it is ultimately limited in its effective scope of controlling the outbreak."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T9","span":{"begin":270,"end":276},"obj":"http://purl.obolibrary.org/obo/GO_0040007"}],"text":"As the outbreak continues, more patients who survived infection will become available to serve as donors to make antisera for 2019-nCoV, and a sizeable stock of antisera could be developed to serve as a treatment for the sickest patients. Unfortunately, the exponential growth of the outbreak would work against this strategy, since the growing number of cases would likely outstrip the ability of previous patients to provide donor plasma as treatment. Moreover, convalescent patient sera would have significant variability in the potency of antiviral effect, making it less ideal 37. While transfusion medicine services should certainly pursue convalescent patient sera as an option right now for patient treatment, it is ultimately limited in its effective scope of controlling the outbreak."}

{"project":"LitCovid-sentences","denotations":[{"id":"T90","span":{"begin":0,"end":238},"obj":"Sentence"},{"id":"T91","span":{"begin":239,"end":453},"obj":"Sentence"},{"id":"T92","span":{"begin":454,"end":585},"obj":"Sentence"},{"id":"T93","span":{"begin":586,"end":794},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As the outbreak continues, more patients who survived infection will become available to serve as donors to make antisera for 2019-nCoV, and a sizeable stock of antisera could be developed to serve as a treatment for the sickest patients. Unfortunately, the exponential growth of the outbreak would work against this strategy, since the growing number of cases would likely outstrip the ability of previous patients to provide donor plasma as treatment. Moreover, convalescent patient sera would have significant variability in the potency of antiviral effect, making it less ideal 37. While transfusion medicine services should certainly pursue convalescent patient sera as an option right now for patient treatment, it is ultimately limited in its effective scope of controlling the outbreak."}